ZYN's FDA approval boosts PM’s non-smokers segment, improving growth fundamentals while existing earnings momentum remains strong. Technical levels show a bullish continuation above the 200-day MA, supporting a short-term upside.

The 6.3% post-announcement rally reflects positive investor sentiment, confirming the ZYN narrative as a key value driver. Across the broader market, trades are favoring risk‑positive themes, keeping PM on a bullish trajectory.

While ZYN approval strengthens upside, exposure to regulatory cycles and competitive pressure remains a long‑term risk, modestly tempering enthusiasm. Nonetheless, the company’s diversified portfolio and strong CAPEX positioning keep a bullish stance.

RSI remains in the 65-70 range, hinting at a sustained bullish bias, and volume spikes align with the ZYN announcement. The 50‑day MA is holding near the spot, indicating a firm short‑term rebound.